Millennium Management’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Millennium Management’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-6,098	Closed	-$43.9K	–	6696
2023 Q2	$43.9K	Sell	6,098 -4,813	-44%	-$34.9K	﹤0.01%	5500
2023 Q1	$80K	Buy	10,911 +3,509	+47%	+$29.8K	﹤0.01%	5496
2022 Q4	$49K	Sell	7,402 -1,223	-14%	-$10.7K	﹤0.01%	5785
2022 Q3	$88K	Sell	8,625 -4,836	-36%	-$61.2K	﹤0.01%	6008
2022 Q2	$164K	Buy	+13,461	New	+$213K	﹤0.01%	5727
2021 Q3	–	Sell	-948	Closed	-$157K	–	7372
2021 Q2	$157K	Buy	+948	New	+$161K	﹤0.01%	6106

Other funds holding TLIS

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Millennium Management's TLIS Position: Q3 2023 in Review

Millennium Management sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2023, closing a stake of 6,098 shares — an estimated $43.9K sold.

Millennium Management first reported a position in TLIS in Q2 2021 and held it in 6 quarters. The position peaked at $164K in Q2 2022. 19 funds tracked by Wall St. Rank hold TLIS as of Q3 2023.

Millennium Management reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2023 after selling out during the quarter.
Millennium Management sold 6,098 Talis Biomedical Corporation Common Stock shares in Q3 2023, an estimated $43.9K.
Millennium Management first reported a position in Talis Biomedical Corporation Common Stock in Q2 2021 and held it in 6 quarters.
Millennium Management's Talis Biomedical Corporation Common Stock position peaked at $164K in Q2 2022.
19 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2023.

Based on Millennium Management's 13F filing for Q3 2023, filed 14 Nov 2023.